Vaishali Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Vaishali Pharma Ltd reported a 39.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 42.8% QoQ and - - YoY.
• The net profit decreased 7.0% QoQ and - - YoY.
• The earnings per share (EPS) of Vaishali Pharma Ltd stood at 0.09 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vaishali Pharma Ltd is a company that operates in the pharmaceutical industry. It specializes in the manufacture and distribution of pharmaceutical products, including a wide range of medications and health-related goods. The company plays a crucial role in the healthcare sector, providing essential drugs and contributing to public health. As of the latest information available, there are no major recent developments, acquisitions, or expansions reported for Vaishali Pharma Ltd. The company continues to focus on its core business of pharmaceutical production and distribution. Detailed information about its specific product lines or strategic initiatives is not available in this context.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Vaishali Pharma Ltd reported a total income of ₹34.29 crores. This represents an increase of 39.4% compared to the previous quarter (Q1FY26), where the total income was ₹24.59 crores. The year-over-year (YoY) performance comparison for total income is not available due to a lack of data for Q2FY25. This quarterly growth in revenue indicates an upward trend in the company's income generation for the reported period. The reported figures for Q2FY25 are not available, therefore, YoY analysis cannot be conducted for the total income.

Profitability

For the second quarter of FY26, Vaishali Pharma Ltd's profit before tax (PBT) was reported at ₹1.66 crores, showing a decrease of 4.6% from ₹1.74 crores in the first quarter of FY26. The tax expenses for Q2FY26 were ₹0.47 crores, slightly increasing by 2.2% from the preceding quarter's tax outlay of ₹0.46 crores. Consequently, the company's profit after tax (PAT) for Q2FY26 stood at ₹1.19 crores, reflecting a decrease of 7.0% from the ₹1.28 crores reported in Q1FY26. Earnings per share (EPS) for Q2FY26 was noted at ₹0.09, with no comparative data available for earlier periods due to zero or unspecified values in Q1FY26 and Q2FY25. The lack of prior year data limits the ability to conduct a year-over-year analysis for profitability metrics.

Operating Metrics

The reported financial data highlights Vaishali Pharma Ltd’s operational efficiency in terms of total expenses, which amounted to ₹32.63 crores in Q2FY26, up 42.8% from ₹22.85 crores in Q1FY26. This indicates a substantial increase in operational costs quarter-over-quarter, which could be attributed to various factors such as production scaling or increased procurement costs. Other operational metrics, such as specific segment performance or operational ratios, are not provided in the available data. Consequently, a detailed analysis of operational efficiency and performance beyond total expense changes is limited. Key financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratios are not calculable with the provided dataset, as it lacks the necessary elements like market capitalization, total debt, and current assets/liabilities. Thus, the analysis focuses mainly on the available revenue and expense data.